Welcome!

News Feed Item

Human Reproductive Technologies: Products and Global Markets

LONDON, Sept. 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Human Reproductive Technologies: Products and Global Markets

https://www.reportbuyer.com/product/1923022/Human-Reproductive-Technologies-Products-and-Global-Markets.html

STUDY GOALS AND OBJECTIVES

The objective of the study is to present a comprehensive, up-to-date look at the market for reproductive technologies and products. Markets are divided according to treatment type and indication. The products in some markets are mature, while products in other markets are just beginning to emerge. The report is directed to decision-makers in the various areas of reproductive drugs and technologies, and it provides insight into those arenas for current and future development.

REASONS FOR STUDY

This BCC Research study is presented to increase the awareness of the global reproductive market by identifying pharmaceutical preparations, devices, technologies and important advancements within the industry. The study analyzes the new therapeutics and technologies for reproductive health and it addresses issues and trends affecting the market. Manufacturers of pharmaceutical products, devices and technologies have stepped up discovery, as the engine driving growth in all markets is research and development.

SCOPE OF STUDY

The report is designed to be a comprehensive business tool to provide an in-depth look at the markets for reproductive drugs and technologies. The geographic scope of the report is global. The report reviews male and female reproductive health, presents standard pharmaceutical treatments and devices, and reviews technologies associated with reproductive health. The report also explores market size, identifies market participants and investigates pipeline products and technologies.
The global market for reproductive technologies and products is divided into categories by treatment type and indication as follows.

• Infertility market—male and female factors, pharmaceuticals and future advancements.
o IVF.
o Assistive reproductive technologies.
o Fertility diagnostics.
• Contraception—pharmaceuticals and devices.
• Sexual dysfunction—pharmaceuticals and devices.

Each area is covered in detail, describing the disorder or treatment involved, identifying current products and treatments in the market in the base year 2013, measuring current market size and identifying current and potential market drivers, forecasting for 2018, assessing current and potential competitors and identifying current competitor market shares for the base year of 2013.

METHODOLOGY AND INFORMATION SOURCES

The information and analysis presented in this BCC Research report are based on extensive, first-hand interviews with primary executives, product managers and clinical specialists in the area of reproductive health. Random surveying provided information about the use of products and how products are obtained. Background information was obtained from various government and business sources, medical journals, and trade magazines and interviews with doctors. Key information from published literature was used to conduct interviews with industry participants to validate and obtain expert opinions on current and future trends in reproductive drugs and technologies in healthcare. Interviews were also used to confirm and/or adjust market size and competitor market share estimates, as well as to formulate market projections.

All market data pertain to the global market at the manufacturer's level. Data are expressed in current U.S. dollars. The base year is 2013; historical data are provided for 2011 and 2012 and forecast data are provided for 2018. Historical, base year and forecast data are provided for each market segment and subsegment. Market share information is provided for each market subsegment for the 2013 base year.

All average annual growth rates are estimated based on the compilation of data, which includes estimated prevalence of conditions, population growth, products in research and development, historical trends, patent expirations and generic competition.

INTENDED AUDIENCE

This report was prepared as a study of the human reproductive technologies marketplace. Information is presented on the human reproductive technologies industry in general, pharmaceuticals and devices, new technology within the market, new and novel drug applications and market-related issues; in many cases actual revenue is given for the period of 2011 and 2012, with projections of trends and compound annual growth rates (CAGRs) from 2013 through 2018.

This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, pharmaceutical directors, product managers and representatives. It also will be of interest to biologists and those interested in the field of reproductive technologies.

ANALYST CREDENTIALS

Mary Anne Crandall is a Medical Analyst, specializing in the pharmaceuticals industry for 20 years, currently working on a Ph.D. She has completed several in-depth studies on various medical topics requiring both expertise and knowledge of the industry.

REPORT HIGHLIGHTS

The total market for reproductive technologies and products is estimated to achieve revenues of nearly $16.1 billion in 2013. In 2018, the forecasted revenues will likely reach $19.6 billion, demonstrating a compound annual growth rate (CAGR) of 4.1%.

This report provides:

• An overview of the market for human reproductive technologies.
• Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Examinations of market sizes in the categories of infertility, artificial reproductive technologies, fertility diagnostics, contraception, and sexual dysfunction, with a division of markets according to treatment type and indication.
• Evaluations of pipeline products and technologies.
• Patent analysis.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR STUDY 2
SCOPE OF STUDY 2
METHODOLOGY AND INFORMATION SOURCES 3
INTENDED AUDIENCE 3
ANALYST CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH ONLINE SERVICES 4
DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018
($ BILLIONS) 7
SUMMARY FIGURE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTION AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($
BILLIONS) 7

CHAPTER 3 INDUSTRY OVERVIEW 9

STRUCTURE AND FUNCTION OF THE REPRODUCTIVE SYSTEM 9
MALE 9
FEMALE 10
Neuroendocrine Regulation 13
Menarche 14
Menstruation Cycle 14
PHASES OF SEXUAL RESPONSES 15
TABLE 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE
SYSTEMS 15
Male Sexual Response 16
Female Sexual Response 16
NEUROHORMONAL CONTROL OF THE FEMALE AND MALE REPRODUCTIVE
SYSTEM 17
Estrogen 18
Progestogens 18
Testosterone 19
EFFECTS OF AGING 19
ISSUES AND TRENDS OF REPRODUCTIVE HEALTH 21
CONTRACEPTIVE INSURANCE 21
OVER-THE-COUNTER BIRTH CONTROL PILLS 21
PREIMPLANTATION GENETIC DIAGNOSIS 22
DESIGNER BABIES 22
NEW USE FOR CONTRACEPTIVES 24
AGING AND INFERTILITY 25
DEATH BY CONTRACEPTIVE PATCH 26
SEXUAL DYSFUNCTION AND CANCER 27
INFERTILITY AND CANCER 28
Chemotherapy 28
Radiation 29
Prevention Strategies 30
Procreative Alternatives 30
SIGNALING PATHWAY FOR FERTILITY TREATMENT 31
MARKETING TACTICS 31
MALE BIRTH CONTROL 32
MERCHANDISING TARGETING WOMEN 32
COUNTERFEIT PRODUCTS 32
SURPLUS EMBRYOS AND FETUSES 33
STEM CELL AND OTHER CONTROVERSIAL ISSUES - SELECTED
INTERNATIONAL VIEWS 35
CONTROVERSIAL DISPOSAL OF EMBRYOS 39
DEMOGRAPHICS 41
UNITED STATES 41
TABLE 2 U.S. LIVE BIRTH RATES, 1960–2012 (THOUSANDS) 41
FIGURE 1 U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS) 42
TABLE 3 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL
POPULATION, THROUGH 2030 (THOUSANDS/%) 42
FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL
POPULATION, 2003-2030 (%) 42
TABLE 4 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST
YEAR: 2000 AND 2008 (PER 1,000 WOMEN) 43
TABLE 5 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR
FORCE STATUS: 1980–2008 44
TABLE 6 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND
MARITAL STATUS (%) 45
EU 45
TABLE 7 BIRTH RATE BY EU COUNTRY AND YEAR, 1960–2011 (PER 1,000
POPULATION (%)) 46
ASIA 47

CHAPTER 4 INFERTILITY MARKET 50

INTRODUCTION AND OVERVIEW OF INFERTILITY 50
DEFINITION OF INFERTILITY 50
ETIOLOGY OF INFERTILITY 50
EVALUATION OF FERTILITY 50
Male Factor 51
Artificial Insemination 52
Vaginal and Cervical Factors 55
Immunological Factors 56
Uterine and Tubal Factors 57
Ovarian Factors 58
UNEXPLAINED INFERTILITY 59
MULTIPLE BIRTHS 60
ASIA FACTOR 61

CHAPTER 5 METHODS OF TREATMENT 63

FERTILITY PHARMACEUTICALS 63
INTRODUCTION AND TYPES 63
Antagon 64
Bravelle 65
Cetrotide 65
Clomid 65
Crinone and Prometrium 66
Fertinex 67
Follistim 67
Gonal-F 67
Humegon 68
Lupron 68
Novarel 68
Ovidrel 69
Parlodel 69
Pregnyl 69
Profasi 69
Prometrium 69
Repronex 69
Serophene 70
TABLE 8 SELECTED PRESCRIPTION FERTILITY DRUGS 70
MARKET REVENUES AND FORECAST 71
TABLE 9 MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.S.
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 71
FUTURE ADVANCEMENTS IN INFERTILITY PRODUCTS 72
CORIFOLLITROPIN ALFA INJECTION 72
PROGESTERONE VAGINAL RING 72
XM17 72
TABLE 10 INFERTILITY DRUGS IN DEVELOPMENT 72
COMPETITIVE ANALYSIS 72
TABLE 11 GLOBAL INFERTILITY PHARMACEUTICAL MANUFACTURERS' ESTIMATED
MARKET SHARE BY REVENUES, 2013 ($ MILLIONS/%) 73
FIGURE 3 INFERTILITY PHARMACEUTICAL MANUFACTURERS' MARKET SHARE BY
REVENUES, 2013 (%) 73

CHAPTER 6 ASSISTIVE REPRODUCTIVE TECHNOLOGIES 75

INTRODUCTION 75
TYPES 75
IVF 75
Ovulation Induction 76
Oocyte Retrieval 76
Intracytoplasmic Sperm Injection (ICSI) 76
Fertilization 77
Embryo Transfer 77
Results of IVF 77
GIFT 78
ZIFT 78
WOMBS FOR RENT 79
OOCYTE DONATION 80
FROZEN EMBRYOS 81
UNITED STATES FERTILITY CLINICS 82
TABLE 12 NATIONAL SUMMARY OF ASSISTIVE REPRODUCTIVE THERAPIES, 2011
(U.S.) 82
TABLE 13 NATIONAL ASSISTIVE REPRODUCTIVE THERAPIES CYCLE PROFILE, 2011
(%) 82
TABLE 14 PREGNANCY SUCCESS RATES, 2011 83
INTERNATIONAL FERTILITY CLINICS 84
TABLE 15 NUMBER OF IVF CENTERS BY SELECT COUNTRIES 84
MARKET REVENUES AND FORECAST 85
TABLE 16 MARKET SIZE OF GLOBAL ASSISTIVE REPRODUCTIVE TECHNOLOGIES AT
U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 85
FUTURE TRENDS IN ASSISTIVE REPRODUCTIVE TECHNOLOGY 85
COMPETITIVE ANALYSIS 87
TABLE 17 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE PRODUCTS' ESTIMATED
MARKET SHARE BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 87
FIGURE 4 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE MARKET SHARES BY
REVENUES, 2013 (%) 87

CHAPTER 7 FERTILITY DIAGNOSTICS 90

INTRODUCTION 90
TYPES 90
Urine Studies 90
Pregnancy Testing 90
Ovulation Testing 91
Sperm Testing 92
Hormone Studies 93
Blood Studies 93
MARKET REVENUES AND FORECAST 94
TABLE 18 MARKET SIZE OF GLOBAL FERTILITY DIAGNOSTICS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 94
COMPETITIVE ANALYSIS 94
TABLE 19 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 ($ MILLIONS/%) 94
FIGURE 5 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 (%) 95
FUTURE ADVANCEMENTS IN DIAGNOSTIC FERTILITY TREATMENT 95
TOTAL INFERTILITY MARKET REVENUES AND FORECAST 96
TABLE 20 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 96
FIGURE 6 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 96

CHAPTER 8 CONTRACEPTION MARKET 98

INTRODUCTION AND OVERVIEW OF CONTRACEPTION 98
TABLE 21 CONTRACEPTIVE STATUS AND USE RATES, U.S. WOMEN AGED 15-44.,
2011 (THOUSANDS) 100
TABLE 22 CONTRACEPTIVE USE RATES BY REGIONS, 2011 (PERCENT) 100
PHARMACEUTICALS 101
Types 101
Oral Contraceptives 101
TABLE 23 MOST COMMONLY USED ORAL AND TRANSDERMAL CONTRACEPTIVES,
2013 103
Alesse 105
Beyaz 105
Brevicon and Norinyl 105
Desogen 105
Estrostep 105
Levlen ED 106
Levora 106
Lo -Loestrin 106
Lo/Ovral 106
Low-Ogestrel 106
Lybrel 106
Microgestin 107
Mircette 107
Natazia 107
Necon 107
Nordette 107
Nor-QD 107
Ortho Evra 108
Ortho Micronor 108
Ortho Tri-Cyclen 108
OrthoCept 108
Ovcon 35 109
Ovral 109
Quartette 109
Safyral 109
Seasonale 109
Tri-Levlen 110
Tri-Norinyl 110
Triphasil 110
Trivora 110
Yasmin 28 110
Zovia 111
Zoely 111
TABLE 24 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH
CONTROL PILLS 111
TABLE 25 POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS 113
TABLE 26 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO 113
OTHER DRUG REGIMENS FOR CONTRACEPTION 114
Depo-Provera 114
Plan B One Step 114
Mifeprex 115
MARKET REVENUES AND FORECAST 115
TABLE 27 MARKET SIZE OF GLOBAL CONTRACEPTIVE PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 116
COMPETITIVE ANALYSIS 116
TABLE 28 GLOBAL CONTRACEPTIVE PHARMACEUTICAL MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 116
FIGURE 7 GLOBAL CONTRACEPTIVE PHARMACEUTICALS MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 116
PRESCRIPTION DEVICES 117
INTRODUCTION AND TYPES 117
Intrauterine Devices 118
NuvaRing 118
Implanon 119
TABLE 29 SELECTED CONTRACEPTIVE DEVICE TREATMENTS 2013 119
MARKET REVENUES AND FORECAST 119
TABLE 30 MARKET SIZE OF GLOBAL CONTRACEPTIVE DEVICES AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 120
COMPETITIVE ANALYSIS 120
TABLE 31 GLOBAL CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 120
FIGURE 8 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 (%) 120
FUTURE ADVANCEMENTS IN CONTRACEPTION 121
TABLE 32 CONTRACEPTIVES IN DEVELOPMENT 121
AG-200-15 122
ARC 122
C31G (SAVVY) 122
FC PATCH 122
LECETTE 122
AG890 123
USHERCELL 123
LEVOSERT IUD 123
TOTAL MARKET REVENUES AND FORECAST 123
TABLE 33 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 123
FIGURE 9 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 124

CHAPTER 9 SEXUAL DYSFUNCTION MARKET 126

INTRODUCTION AND OVERVIEW 126
TYPES OF SEXUAL DYSFUNCTION 126
CAUSES OF SEXUAL DYSFUNCTION 127
DEMOGRAPHICS OF SEXUAL DYSFUNCTION 127
PHARMACEUTICALS 128
Introduction and Types 128
Viagra 128
Cialis 128
Levitra 128
Staxyn 129
Stendra/Spendra 129
Yohimbine 129
Caverject 129
MUSE 129
TABLE 34 SELECTED SEXUAL DYSFUNCTION PHARMACEUTICAL TREATMENTS 130
MARKET REVENUES AND FORECAST 130
TABLE 35 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 131
COMPETITIVE ANALYSIS 131
TABLE 36 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 131
FIGURE 10 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 (%) 131
DEVICES 132
Introduction and Types 132
SomaTherapy-ED SOMAerect Stf 132
Viberect 133
Erectaid Classic System 133
AMS Inflatable Penile Implant 134
Coloplast Titan OTR 134
TABLE 37 SELECTED SEXUAL DYSFUNCTION DEVICE TREATMENTS 134
MARKET REVENUES AND FORECAST 134
TABLE 38 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION DEVICES AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 135
COMPETITIVE ANALYSIS 135
TABLE 39 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 135
FIGURE 11 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 135
FUTURE ADVANCEMENTS IN SEXUAL DYSFUNCTION 136
TABLE 40 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT 136
Flibanserin 137
Femprox 137
LibiGel 137
Lybrido and Lybridos 137
Tefina 138
Topiglan 138
Zoraxel 138
Zydena (udenafil) 138
TOTAL MARKET REVENUES AND FORECAST 138
TABLE 41 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 139
FIGURE 12 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 139

CHAPTER 10 PATENTS 141

PATENT ANALYSIS BY MANUFACTURER 141
TABLE 42 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS
AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT 141
PATENTS BY APPLICATION 141
INFERTILITY TREATMENTS 141
CONTRACEPTION 142
SEXUAL DYSFUNCTION 142

CHAPTER 11 LEADING MARKET MANUFACTURERS 144

TABLE 43 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT
MANUFACTURERS, 1976–PRESENT 144

CHAPTER 12 TOTAL MARKET 147

TABLE 44 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($
BILLIONS)
147
TOTAL GLOBAL MARKET FOR REPRODUCTIVE TECHNOLOGIES AND PRODUCTS
BY REGION 147
TABLE 45 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2013 ($ MILLIONS/%) 148
FIGURE 13 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2013 (%) 148
TABLE 46 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2018 ($ MILLIONS/%) 149
FIGURE 14 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2018 (%) 149
TOTAL MARKET SIZE BY CATEGORY 149
TABLE 47 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
THROUGH 2018 ($ MILLIONS)
150
FIGURE 15 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
2011–2018 ($ MILLIONS)
150
TABLE 48 TOTAL ESTIMATED GLOBAL REVENUES, MARKET SHARE AND NUMBER
OF MANUFACTURERS OF REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY
MARKET SEGMENT, 2013 ($ MILLIONS/%)
151
FIGURE 16 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2013 151
FIGURE 17 MARKET SHARE BY MARKET SEGMENT, 2013 (%) 151
INDUSTRY PARTICIPANTS BY CATEGORY 152
TABLE 49 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY 152
TOTAL MARKET SIZE BY PRODUCT TYPE 154
TABLE 50 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 154
FIGURE 18 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011–2018 ($ MILLIONS) 155

CHAPTER 13 PARTICIPATING COMPANIES 157

COMPANY PROFILES 157
ACTAVIS, INC 157
BAYER AG 157
BRISTOL-MYERS SQUIBB CO. 159
CHURCH & DWIGHT COMPANY INC. 159
COOPERSURGICAL INC. 159
ELI LILLY & CO. 160
EMD SERONO, INC 160
FERRING PHARMACEUTICALS 161
GLAXOSMITHKLINE PLC 161
JANSSEN PHARMACEUTICAL 162
MERCK INC. 162
NOVARTIS INTERNATIONAL AG 163
PFIZER INC. 163
PRINCETON BIOMEDITECH CORP. 164
QUIDEL CORP 164
VIVUS INC. 165

CHAPTER 14 APPENDIX A 167

SELECTED LIST OF U.S. FERTILITY CLINICS 167
ALABAMA 167
ARIZONA 167
CALIFORNIA 168
COLORADO 169
CONNECTICUT 170
DISTRICT OF COLUMBIA 170
FLORIDA 170
GEORGIA 171
IDAHO 171
ILLINOIS 171
INDIANA 172
KANSAS 173
MAINE 173
MARYLAND 173
MASSACHUSETTS 173
MICHIGAN 174
MINNESOTA 174
MONTANA 174
NEVADA 174
NEW HAMPSHIRE 175
NEW JERSEY 175
NEW YORK 176
NORTH CAROLINA 176
OREGON 176
RHODE ISLAND 177
SOUTH CAROLINA 177
SOUTH DAKOTA 177
TEXAS 177
UTAH 178
VIRGINIA 178
WASHINGTON 178
SELECTED LIST OF FERTILITY CLINICS IN OTHER REGIONS 179
ASIAN FERTILITY CLINICS 179
AUSTRIA 180
Innsbruck 180
Vienna 180
SWITZERLAND 181
Basel 181
Geneva 181
Zurich 182
GERMANY 182
FRANCE 183
Paris 183
ITALY 183
Naples 183
Rome 184
GREAT BRITAIN 184
London 184

CHAPTER 15 APPENDIX B: LIST OF COMPANIES 187

TABLE 51 LIST OF COMPANIES 187

LIST OF TABLES

SUMMARY TABLE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018
($ BILLIONS)
7
TABLE 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE
SYSTEMS 15
TABLE 2 U.S. LIVE BIRTH RATES, 1960–2012 (THOUSANDS) 41
TABLE 3 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL
POPULATION, THROUGH 2030 (THOUSANDS/%) 42
TABLE 4 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR:
2000 AND 2008 (PER 1,000 WOMEN) 43
TABLE 5 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR
FORCE STATUS: 1980–2008 44
TABLE 6 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND
MARITAL STATUS (%) 45
TABLE 7 BIRTH RATE BY EU COUNTRY AND YEAR, 1960–2011 (PER 1,000
POPULATION (%)) 46
TABLE 8 SELECTED PRESCRIPTION FERTILITY DRUGS 70
TABLE 9 MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.S.
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 71
TABLE 10 INFERTILITY DRUGS IN DEVELOPMENT 72
TABLE 11 GLOBAL INFERTILITY PHARMACEUTICAL MANUFACTURERS' ESTIMATED
MARKET SHARE BY REVENUES, 2013 ($ MILLIONS/%) 73
TABLE 12 NATIONAL SUMMARY OF ASSISTIVE REPRODUCTIVE THERAPIES, 2011
(U.S.) 82
TABLE 13 NATIONAL ASSISTIVE REPRODUCTIVE THERAPIES CYCLE PROFILE, 2011 (%) 82
TABLE 14 PREGNANCY SUCCESS RATES, 2011 83
TABLE 15 NUMBER OF IVF CENTERS BY SELECT COUNTRIES 84
TABLE 16 MARKET SIZE OF GLOBAL ASSISTIVE REPRODUCTIVE TECHNOLOGIES AT
U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 85
TABLE 17 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE PRODUCTS' ESTIMATED
MARKET SHARE BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 87
TABLE 18 MARKET SIZE OF GLOBAL FERTILITY DIAGNOSTICS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 94
TABLE 19 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 ($ MILLIONS/%) 94
TABLE 20 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 96
TABLE 21 CONTRACEPTIVE STATUS AND USE RATES, U.S. WOMEN AGED 15-44.,
2011 (THOUSANDS) 100
TABLE 22 CONTRACEPTIVE USE RATES BY REGIONS, 2011 (PERCENT) 100
TABLE 23 MOST COMMONLY USED ORAL AND TRANSDERMAL CONTRACEPTIVES,
2013 103
TABLE 24 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH
CONTROL PILLS 111
TABLE 25 POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS 113
TABLE 26 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO 113
TABLE 27 MARKET SIZE OF GLOBAL CONTRACEPTIVE PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 116
TABLE 28 GLOBAL CONTRACEPTIVE PHARMACEUTICAL MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 116
TABLE 29 SELECTED CONTRACEPTIVE DEVICE TREATMENTS 2013 119
TABLE 30 MARKET SIZE OF GLOBAL CONTRACEPTIVE DEVICES AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 120
TABLE 31 GLOBAL CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 120
TABLE 32 CONTRACEPTIVES IN DEVELOPMENT 121
TABLE 33 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 123
TABLE 34 SELECTED SEXUAL DYSFUNCTION PHARMACEUTICAL TREATMENTS 130
TABLE 35 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ BILLIONS) 131
TABLE 36 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 131
TABLE 37 SELECTED SEXUAL DYSFUNCTION DEVICE TREATMENTS 134
TABLE 38 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION DEVICES AT ESTIMATED
MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 135
TABLE 39 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 ($ MILLIONS/%) 135
TABLE 40 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT 136
TABLE 41 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 139
TABLE 42 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS
AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT 141
TABLE 43 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT
MANUFACTURERS, 1976–PRESENT 144
TABLE 44 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS AT ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($
BILLIONS)
147
TABLE 45 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2013 ($ MILLIONS/%) 148
TABLE 46 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS ESTIMATED
MARKET REVENUES BY SELECTED GEOGRAPHIC REGIONS, 2018 ($ MILLIONS/%) 149
TABLE 47 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
THROUGH 2018 ($ MILLIONS)
150
TABLE 48 TOTAL ESTIMATED GLOBAL REVENUES, MARKET SHARE AND NUMBER OF
MANUFACTURERS OF REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET
SEGMENT, 2013 ($ MILLIONS/%)
151
TABLE 49 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY 152
TABLE 50 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, THROUGH 2018 ($ MILLIONS) 154
TABLE 51 LIST OF COMPANIES 187

LIST OF FIGURES

SUMMARY FIGURE TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES
AND PRODUCTION AT ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($
BILLIONS)
7
FIGURE 1 U.S. LIVE BIRTH RATES, 1960-2012 (THOUSANDS) 42
FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL
POPULATION, 2003-2030 (%) 42
FIGURE 3 INFERTILITY PHARMACEUTICAL MANUFACTURERS' MARKET SHARE BY
REVENUES, 2013 (%) 73
FIGURE 4 GLOBAL INFERTILITY ASSISTIVE REPRODUCTIVE MARKET SHARES BY
REVENUES, 2013 (%) 87
FIGURE 5 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARES BY ESTIMATED
REVENUES, 2013 (%) 95
FIGURE 6 MARKET SIZE OF GLOBAL INFERTILITY TREATMENTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 96
FIGURE 7 GLOBAL CONTRACEPTIVE PHARMACEUTICALS MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 116
FIGURE 8 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARES BY
ESTIMATED REVENUES, 2013 (%) 120
FIGURE 9 MARKET SIZE OF GLOBAL CONTRACEPTIVE PRODUCTS AT ESTIMATED
MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 124
FIGURE 10 GLOBAL SEXUAL DYSFUNCTION PHARMACEUTICALS MANUFACTURER
MARKET SHARES BY ESTIMATED REVENUES, 2013 (%) 131
FIGURE 11 GLOBAL SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET
SHARES BY ESTIMATED REVENUES, 2013 (%) 135
FIGURE 12 MARKET SIZE OF GLOBAL SEXUAL DYSFUNCTION TREATMENTS AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011-2018 ($ MILLIONS) 139
FIGURE 13 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2013 (%) 148
FIGURE 14 GLOBAL REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET
SHARE BY SELECTED GEOGRAPHIC REGIONS, 2018 (%) 149
FIGURE 15 TOTAL REVENUES OF GLOBAL REPRODUCTIVE TECHNOLOGIES AND
PRODUCTS BY CATEGORY AT ESTIMATED MANUFACTURERS' SALES LEVELS,
2011–2018 ($ MILLIONS)
150
FIGURE 16 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2013 151
FIGURE 17 MARKET SHARE BY MARKET SEGMENT, 2013 (%) 151
FIGURE 18 TOTAL REVENUES OF GLOBAL REPRODUCTION PRODUCTS BY TYPE AT
ESTIMATED MANUFACTURERS' SALES LEVELS, 2011–2018 ($ MILLIONS) 155

Read the full report:
Human Reproductive Technologies: Products and Global Markets

https://www.reportbuyer.com/product/1923022/Human-Reproductive-Technologies-Products-and-Global-Markets.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abil...
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Actian Corporation has announced the latest version of the Actian Vector in Hadoop (VectorH) database, generally available at the end of July. VectorH is based on the same query engine that powers Actian Vector, which recently doubled the TPC-H benchmark record for non-clustered systems at the 3000GB scale factor (see tpc.org/3323). The ability to easily ingest information from different data sources and rapidly develop queries to make better business decisions is becoming increasingly importan...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
SYS-CON Events announced today Telecom Reseller has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...